Clinical Trials Browser

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Epstein-Barr Virus Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05831111 2025-09-30

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Phase 1 Active not recruiting

482 enrolled

Infections, Infectious Mononucleosis, Virus Diseases, Epstein-Barr Virus Infections

NCT05011058 2025-07-28

NAVAL-1

Phase 2 Terminated

102 enrolled 28 charts

Epstein-Barr Virus Infections, Pyloric Stenosis, Hypertrophic

NCT05592626 2025-07-09

START-001

Phase 1/2 Recruiting

365 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06429800 2025-04-24

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Phase 1 Withdrawn

Lupus Erythematosus, Systemic, Lupus Nephritis, Epstein-Barr Virus Infections

NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase 1/2 Terminated

12 enrolled 8 charts

Head & Neck

Nasopharyngeal Carcinoma, Carcinoma, Head and Neck Neoplasms, Stomatognathic Diseases, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Nose Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Pharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT04308278 2024-10-30

EBVAST

Phase 4 Recruiting

88 enrolled

Epstein-Barr Virus Infections

NCT05305040 2024-05-16

Prevent

Phase 2/3 Terminated

451 enrolled 10 charts

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT04693637 2024-05-09

Prevent

Phase 2/3 Completed

26 enrolled 16 charts

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT03283826 2024-02-23

EMBOLD

Phase 1/2 Terminated

134 enrolled

Autoimmune Diseases, Demyelinating Diseases, Inflammation, Multiple Sclerosis, Epstein-Barr Virus Infections, Multiple Sclerosis, Chronic Progressive

NCT03682055 2023-08-15

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Phase 1/2 Terminated

14 enrolled 13 charts

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT02578641 2023-06-28

VANCE

Phase 3 Completed

330 enrolled 18 charts

Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Nose Neoplasms, Epstein-Barr Virus Infections

NCT02108522 2021-07-20

CHARMS

Phase NA Completed

82 enrolled 20 charts

Adenoviridae Infections, Cytomegalovirus Infections, Infections, Epstein-Barr Virus Infections

NCT02000817 2019-06-24

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

Phase 1/2 Completed

30 enrolled 21 charts

Cytokine Release Syndrome, Diabetes Mellitus, Diabetes Mellitus, Type 1, Epstein-Barr Virus Infections

NCT01570283 2019-05-30

ARMS

Phase 1/2 Completed

21 enrolled 10 charts

Adenoviridae Infections, Virus Diseases, Epstein-Barr Virus Infections

NCT02763254 2019-03-26

CIVIC

Phase 2 Terminated

1 enrolled 9 charts

Lymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT01948180 2019-03-13

CITADEL

Phase 2 Terminated

15 enrolled

Lymphoid

Epstein-Barr Virus Infections, Lymphoma, Extranodal NK-T-Cell

NCT02269943 2018-12-12

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

36 enrolled 24 charts

Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Epstein-Barr Virus Infections

NCT02229981 2017-12-07

ABC-102

Phase 1/2 Withdrawn

LymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT00129584 2009-08-18

Endobronchial Valve for Emphysema Palliation Trial (VENT)

Phase 3 Completed

270 enrolled

Emphysema, Epstein-Barr Virus Infections, Pulmonary Disease, Chronic Obstructive

NCT00430534 2007-02-02

Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

Phase 2 Completed

200 enrolled

Infections, Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT00002026 2005-06-24

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

Phase NA Completed

Head & Neck

AIDS-Related Complex, Leukoplakia, Oral, HIV Infections, AIDS-Related Opportunistic Infections, Leukoplakia, Hairy, Epstein-Barr Virus Infections

Clinical Trials

ALLELE

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NAVAL-1

START-001

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

EBVAST

Prevent

Prevent

EMBOLD

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

VANCE

CHARMS

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

ARMS

CIVIC

CITADEL

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

ABC-102

Endobronchial Valve for Emphysema Palliation Trial (VENT)

Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)